澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dalteparin sodium, quantity: 10000 anti-xa iu/ml - injection, solution - excipient ingredients: water for injections; sodium chloride - prophylaxis against thrombotic complications during haemodialysis and treatment of acute deep vein thrombosis (dvt). extended treatment of symptomatic venous thromboembolism (vte) (proximal deep vein thrombosis and/or pulmonary embolism) to reduce the recurrence of vte in patients with solid tumour cancers. treatment of unstable coronary artery disease, i.e. unstable angina and non-st-elevation myocardial infarction (also known as non-q-wave myocardial infarction). prophylaxis against thrombo-embolic complications in the peri- or postoperative period of surgery.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dalteparin sodium, quantity: 7500 anti-xa iu - injection, solution - excipient ingredients: water for injections; sodium chloride - prophylaxis against thrombotic complications during haemodialysis and treatment of acute deep vein thrombosis (dvt). extended treatment of symptomatic venous thromboembolism (vte) (proximal deep vein thrombosis and/or pulmonary embolism) to reduce the recurrence of vte in patients with solid tumour cancers. treatment of unstable coronary artery disease, i.e. unstable angina and non-st-elevation myocardial infarction (also known as non-q-wave myocardial infarction). prophylaxis against thrombo-embolic complications in the peri- or postoperative period of surgery.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dalteparin sodium, quantity: 12500 anti-xa iu - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - prophylaxis against thrombotic complications during haemodialysis and treatment of acute deep vein thrombosis (dvt). extended treatment of symptomatic venous thromboembolism (vte) (proximal deep vein thrombosis and/or pulmonary embolism) to reduce the recurrence of vte in patients with solid tumour cancers. treatment of unstable coronary artery disease, i.e. unstable angina and non-st-elevation myocardial infarction (also known as non-q-wave myocardial infarction). prophylaxis against thrombo-embolic complications in the peri- or postoperative period of surgery.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dalteparin sodium, quantity: 15000 anti-xa iu - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - prophylaxis against thrombotic complications during haemodialysis and treatment of acute deep vein thrombosis (dvt). extended treatment of symptomatic venous thromboembolism (vte) (proximal deep vein thrombosis and/or pulmonary embolism) to reduce the recurrence of vte in patients with solid tumour cancers. treatment of unstable coronary artery disease, i.e. unstable angina and non-st-elevation myocardial infarction (also known as non-q-wave myocardial infarction). prophylaxis against thrombo-embolic complications in the peri- or postoperative period of surgery.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dalteparin sodium, quantity: 18000 anti-xa iu - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections - prophylaxis against thrombotic complications during haemodialysis and treatment of acute deep vein thrombosis (dvt). extended treatment of symptomatic venous thromboembolism (vte) (proximal deep vein thrombosis and/or pulmonary embolism) to reduce the recurrence of vte in patients with solid tumour cancers. treatment of unstable coronary artery disease, i.e. unstable angina and non-st-elevation myocardial infarction (also known as non-q-wave myocardial infarction). prophylaxis against thrombo-embolic complications in the peri- or postoperative period of surgery.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dalteparin sodium, quantity: 5000 anti-xa iu - injection, solution - excipient ingredients: water for injections - prophylaxis against thrombotic complications during haemodialysis and treatment of acute deep vein thrombosis (dvt). extended treatment of symptomatic venous thromboembolism (vte) (proximal deep vein thrombosis and/or pulmonary embolism) to reduce the recurrence of vte in patients with solid tumour cancers. treatment of unstable coronary artery disease, i.e. unstable angina and non-st-elevation myocardial infarction (also known as non-q-wave myocardial infarction). prophylaxis against thrombo-embolic complications in the peri- or postoperative period of surgery.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dalteparin sodium, quantity: 2500 anti-xa iu - injection, solution - excipient ingredients: water for injections; sodium chloride - prophylaxis against thrombotic complications during haemodialysis and treatment of acute deep vein thrombosis (dvt). extended treatment of symptomatic venous thromboembolism (vte) (proximal deep vein thrombosis and/or pulmonary embolism) to reduce the recurrence of vte in patients with solid tumour cancers. treatment of unstable coronary artery disease, i.e. unstable angina and non-st-elevation myocardial infarction (also known as non-q-wave myocardial infarction). prophylaxis against thrombo-embolic complications in the peri- or postoperative period of surgery.

以色列 - 英文 - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - dalteparin sodium - solution for injection - dalteparin sodium 10000 iu/ml - dalteparin - prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. treatment of acute deep venous thrombosis and/or pulmonary embolism. unstable coronary artery disease. thromboprophylaxis in conjunction with surgery. prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections. cancer patients : treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - dalteparin sodium 10000 iu/ml - solution for injection - 10000 iu/ml - active: dalteparin sodium 10000 iu/ml excipient: sodium chloride water for injection - · for the prevention of clotting in the extracorporeal system during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - dalteparin sodium 12500 iu/ml - solution for injection - 12500 iu/ml - active: dalteparin sodium 12500 iu/ml excipient: water for injection - · for the prevention of clotting in the extracorporeal system during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency